NCT03904849

Cannabidiol for Alcohol Use Disorder

A Pilot Human Laboratory Study of Cannabidiol in Alcohol Use Disorder

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 21 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether cannabidiol, relative to placebo, affects subjective response to alcohol or alcohol drinking.

Detailed description

This study will examine the effects of Epidiolex among adults who drink alcohol heavily but who are not seeking treatment for their alcohol use. Epidiolex is an FDA-approved formulation of cannabidiol, the primary non-psychoactive constituent of cannabis. Participants in the study will be randomly assigned to take Epidiolex or placebo for 8 days. There are 3 study visits, including a day-long visit in the laboratory.

Conditions

• Alcohol Use Disorder

Interventions

Type	Name	Description
DRUG	Cannabidiol	Cannabidiol oral solution
DRUG	Placebo	Placebo oral solution

Timeline

• Start date: 2019-10-01
• Primary completion: 2020-04-30
• Completion: 2020-04-30
• First posted: 2019-04-05
• Last updated: 2024-09-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study